Morgan Stanley analyst Michael Cyprys lowered the firm's price target on CME Group to $353 from $362 and keeps an Overweight rating on the shares. The firm sees CME "extending its futures exchange moat and paving way for new growth vectors that are not yet in the price," but is modestly lowering its 2027 EPS estimate by 2.5% to reflect a softer rate per contract outlook, the analyst tells investors.
